Key Highlights

• Echo IQ traded at AUD 0.57 in the cited early-trade snapshot, up 10.68%.

• In the same snapshot, the All Ordinaries rose 0.36%.

• Echo IQ applies artificial intelligence to echocardiogram and related clinical data.

• Echo IQ’s outlook will depend on regulatory progress, clinical evidence, customer adoption, reimbursement pathways and the company’s ability to fund commercial expansion.

Echo IQ (ASX:EIQ) traded at AUD 0.57 at about 10:30am AEST on 17 September 2026, up 10.68% from the previous close, while the All Ordinaries rose 0.36%. The healthcare technology company develops artificial-intelligence software intended to help clinicians identify structural heart disease from cardiac data.

AI-Assisted Cardiac Assessment

Echo IQ applies artificial intelligence to echocardiogram and related clinical data. Its technology is designed to support the identification of conditions such as aortic stenosis and heart failure, giving clinicians another tool when reviewing patients.

Commercial progress depends on regulatory clearances, clinical adoption and integration into existing healthcare workflows. The company must also demonstrate that its products can deliver useful results consistently in real-world settings.

Commercialisation Remains the Main Test

As an early-stage medical technology company, Echo IQ must convert product development and regulatory progress into recurring revenue. Hospital procurement cycles, reimbursement arrangements and clinician acceptance can affect the timing of adoption.

Cash management is also important because software development, clinical evidence and market entry require continued Investment before the Business reaches scale.

Industry Trends and Market Context

Artificial intelligence is being introduced across medical imaging and clinical decision support. Adoption is shaped by evidence, regulation, data security and the ability to fit new tools into established care pathways.

Investment Risks and Challenges

Key risks include regulatory delays, slow customer adoption, limited revenue, funding requirements, cyber security and competition from other diagnostic technologies.

Bullish and Bearish Perspectives

The bullish case centres on a large clinical need, regulatory progress and the potential for scalable software revenue. The bearish case focuses on adoption risk, cash use, reimbursement uncertainty and the time required to build a commercial healthcare platform.

About Echo IQ

Echo IQ Limited is an ASX-listed healthcare technology company developing artificial-intelligence software for cardiac assessment and clinical decision support.

Echo IQ’s outlook will depend on regulatory progress, clinical evidence, customer adoption, reimbursement pathways and the company’s ability to fund commercial expansion.